Disease · MONDO_0011908
Trials29
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
1 to 20 of 29
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01522976 | Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | Phase 2 | 282 | 2016-03-22 | Chronic Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia | AZACITIDINE, LENALIDOMIDE, VORINOSTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02103478 | Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) | Phase 1/2 | 130 | 2020-10-19 | Myelodysplastic Syndrome, MDS | CEDAZURIDINE, DECITABINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04802161 | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | Phase 2 | 49 | 2025-12-19 | Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm | CYTARABINE, DAUNORUBICIN, POMALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00953758 | A Study Of PF-04449913 In Select Hematologic Malignancies | Phase 1 | 47 | 2024-04-25 | Hematologic Malignancies | GLASDEGIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01824693 | Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | Phase 2 | 30 | 2018-12-05 | Juvenile Myelomonocytic Leukemia | BUSULFAN, CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE, MELPHALAN | Its record names the disease | ClinicalTrials.gov |
| NCT00450450 | Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | Phase 3 | 27 | 2017-05-09 | Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Chronic Phase Chronic Myelogenous Leukemia, de Novo Myelodysplastic Syndromes, Juvenile Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Childhood Acute Lymphoblastic Leukemia, Secondary Myelodysplastic Syndromes | FILGRASTIM | Its record names the disease | ClinicalTrials.gov |
| NCT00167219 | Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML) | Phase 1/2 | 15 | 2023-11-07 | Juvenile Myelomonocytic Leukemia | BUSULFAN, CYCLOPHOSPHAMIDE, MELPHALAN | Its record names the disease | ClinicalTrials.gov |
| NCT03190915 | Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Phase 2 | 10 | 2024-07-16 | Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1 | TRAMETINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00509600 | Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia | Phase 2 | 1 | 2010-12-02 | Leukemia | ETANERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT00609739 | Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation | Phase 1/2 | 1 | 2012-03-02 | Leukemia | CYTARABINE, MITOXANTRONE | Its record names the disease | ClinicalTrials.gov |
| NCT00025038 | Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia | Phase 2 | 100 | Juvenile Myelomonocytic Leukemia | CYCLOPHOSPHAMIDE, CYTARABINE, FLUDARABINE PHOSPHATE, ISOTRETINOIN, TIPIFARNIB | Its record names the disease | ClinicalTrials.gov | |
| NCT03418038 | Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | Phase 2 | 80 | Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia | ASCORBIC ACID, CARBOPLATIN, CISPLATIN, CYTARABINE, DECITABINE, DEXAMETHASONE, ETOPOSIDE, GEMCITABINE HYDROCHLORIDE, IFOSFAMIDE, OXALIPLATIN, RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02333058 | Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies | Phase 2 | 70 | Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukaemias (AML), Myelodysplastic Syndromes (MDS), Juvenile Myelomonocytic Leukaemias (JMML) | FLUDARABINE, THIOTEPA, TREOSULFAN | Its record names the disease | ClinicalTrials.gov | |
| NCT05849662 | A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | Phase 1/2 | 58 | Leukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1, CBL Syndrome | AZACITIDINE, CYTARABINE, FLUDARABINE, TRAMETINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT01110473 | ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies | Phase 1 | 52 | Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, B-cell Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia | AZACITIDINE, ILORASERTIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01133886 | Use of Decitabine in Myelodysplastic Syndrome (MDS) Following Azacitidine (AZA) Failure | Phase 2 | 50 | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | DECITABINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04024761 | A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation | Phase 1 | 50 | Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Juvenile Myelomonocytic Leukemia | ALDESLEUKIN | Its record names the disease | ClinicalTrials.gov | |
| NCT05817955 | Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN | Phase 2 | 50 | MDS/MPN | AZACITIDINE, RUXOLITINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT00697671 | Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies | Phase 1 | 48 | Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma | ALDESLEUKIN, CLOFARABINE, CYCLOPHOSPHAMIDE, ETOPOSIDE, TROCULEUCEL | Its record names the disease | ClinicalTrials.gov | |
| NCT04273802 | CPX-351 in Higher Risk Myelodysplastic Syndromes | Phase 1/2 | 40 | Myelodysplastic Syndromes | CYTARABINE, DAUNORUBICIN | Open Targets' reading of its record | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011908/trials